20102014
Om du gjort några ändringar i Pure kommer de visas här snart.

Publikationer 2010 2014

Deregulation of COMMD1 Is Associated with Poor Prognosis in Diffuse Large B-cell Lymphoma

Taskinen, M., Louhimo, R., Koivula, S., Chen, P., Rantanen, V., Holte, H., Delabie, J., Karjalainen-Lindsberg, M-L., Bjorkholm, M., Fluge, O., Pedersen, L. M., Fjorden, K., Jerkeman, M., Eriksson, M., Hautaniemi, S. & Leppä, S., 13 mar 2014, I : PLoS One. 9, 3, 11 s., 91031.

Forskningsoutput: TidskriftsbidragArtikelVetenskapligPeer review

Öppen tillgång
Fil

Alternative Splicing and Expression of Class II Tubulin Beta (TUBB2B) Are Associated with Outcome in Diffuse Large B-Cell Lymphoma

Taskinen, M., Koivula, S., Chen, P., Karjalainen-Lindsberg, M-L., Cervera, A., Delabie, J., Holte, H., Hautaniemi, S. & Leppa, S., 16 nov 2012, I : Blood. 120, 21, 2 s., Meeting Abstract: 1557.

Forskningsoutput: TidskriftsbidragMötesabstraktForskningPeer review

Use of exon-based transcriptome profiling to identify novel signaling pathways and survival-associated genes in diffuse large B-cell lymphoma

Leppa, S., Taskinen, M., Koivula, S., Chen, P., Louhimo, R., Delabie, J., Karjalainen-Lindsberg, M-L., Bjorkholm, M., Fluge, O., Pedersen, L. M., Rydstrom, K., Jerkeman, M., Eriksson, M., Hautaniemi, S., Holte, H. & Nordic Lymphoma Grp, 20 maj 2012, I : Journal of Clinical Oncology. 30, 15, 1 s., Meeting Abstract: 8074.

Forskningsoutput: TidskriftsbidragMötesabstraktForskningPeer review

INTEGRATIVE GENOMIC PROFILING OF HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS LESS THAN 65 YEARS OLD TREATED WITH DOSE-DENSE CHEMOIMMUNOTHERAPY AND CNS PROPHYLAXIS

Koivula, S., Taskinen, M., Louhimo, R., Chen, P., Delabie, J., Holte, H., Karjalainen-Lindsberg, M., Bjorkholm, M., Fluge, O., Pedersen, L. M., Jerkeman, M., Eriksson, M., Hautaniemi, S. & Leppa, S., jun 2011, I : Annals of Oncology. 22, s. 207-207 1 s.

Forskningsoutput: TidskriftsbidragMötesabstraktForskningPeer review

Exon-Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B-Cell/Follicular Grade 3 Lymphoma Patients Treated with Dose-Dense Chemoimmuno-therapy and CNS Prophylaxis. Results From a Nordic Lymphoma Group Phase II Study.

Koivula, S., Taskinen, M., Chen, P., Holte, H., Delabie, J., Karjalainen-Lindsberg, M-L., Bjorkholm, M., Fluge, O., Pedersen, L. M., Jerkeman, M., Eriksson, M., Hautaniemi, S. & Leppa, S., 19 nov 2010, I : Blood. 116, 21, s. 1281-1281 1 s.

Forskningsoutput: TidskriftsbidragMötesabstraktForskningPeer review